242 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Approved for marketing Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
2 Available PFO ACCESS Registry
Conditions: Patent Foramen Ovale;   Stroke
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
3 Temporarily not available Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
4 Available Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
Conditions: Toxicity Due to Chemotherapy;   Impaired 5FU Elimination
Intervention: Drug: uridine triacetate
5 Available Post Study Continuation of C7 for G1D
Conditions: Glut1 Deficiency Syndrome;   Glucose Transporter Type 1 Deficiency Syndrome
Intervention: Drug: Triheptanoin
6 No longer available This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma
Intervention: Drug: Plerixafor
7 Approved for marketing BMN 110 US Expanded Access Program
Conditions: Mucopolysaccharidosis IVA;   Morquio A Syndrome;   MPS IVA
Intervention: Drug: BMN 110
8 No longer available Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Condition: West Nile Virus Infection
Intervention: Biological: MGAWN1
9 Available Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders;   Pyruvate Carboxylase Deficiency, Type B;   Acyl-coA Dehydrogenase, Type 9
Intervention: Drug: triheptanoin
10 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
Condition: HIV Infections
Intervention: Drug: Tipranavir
11 Available Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents
Conditions: Fanconi Anemia;   Autosomal or Sex Linked Recessive Genetic Disease;   Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases.;   Hematopoiesis Maintainance.
Interventions: Genetic: human whole exome;   Genetic: whole genomic
12 No longer available Stiripentol in Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: stiripentol
13 Available Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
14 Approved for marketing Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Conditions: Cystic Fibrosis;   Pseudomonas Aeruginosa
Intervention: Drug: Aztreonam lysine
15 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
16 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
17 Unknown  Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib/Dexamethasone/Melphalan
18 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
19 Approved for marketing Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Drug: cabozantinib
20 Available Bivalirudin foR Acute Myocardial Infarction underGoing Angioplasty in CHinese patienTs.
Condition: Acute Myocardial Infarction
Intervention: Drug: Bivalirudin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years